Transcriptional regulation of Bcl-2 gene by the PR/SET domain family member PRDM10

Na Chen¹, Taobo Hu², Yuanyuan Gui¹, Jieying Gao¹, Zhihong Li² and Shi Huang¹

¹Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China
²Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

ABSTRACT

Bcl-2 (B-cell lymphoma 2) protein is localized in the outer membrane of mitochondria, where it plays an important role in promoting cellular survival and inhibiting the actions of pro-apoptotic proteins. PRDM10 is a member of the PR/SET family of epigenetic regulators and may play a role in development and cell differentiation. Here we show that human PRDM10 contributes to the transcriptional regulation of human Bcl-2 gene. We found that PRDM10-depletion in human cells reduced the expression of Bcl-2 protein and over-expression of PRDM10 promoted Bcl-2 protein expression. Furthermore, luciferase reporter activity of Bcl-2 gene P1 promoter was significantly increased in cells co-transfected with PRDM10, and PRDM10 was able to bind to the Bcl-2 P1 promoter in vivo. Using The Cancer Genome Atlas (TCGA) data set, we found weak positive correlation between PRDM10 and Bcl-2 in several cancer types including cancers of the breast, colon, and lung tissues. These data identify a novel function for PRDM10 protein and provide insights on the transcriptional control of Bcl-2 expression.

INTRODUCTION

The B cell lymphoma-2 (Bcl-2) protein belongs to the Bcl-2 protein family and plays an important role in the regulation of programmed cell death or apoptosis (Chao & Korsmeyer, 1998; Letai et al., 2002). Bcl-2 over-expression has been observed in a wide variety of cancer (Aird et al., 2019; De Veirman et al., 2018; Wu et al., 2001; Martin & Dowsett, 2013; Reed et al., 1994). In addition, the increased cell survival due to overexpression of Bcl-2 has been shown to contribute to tumor development and resistance to various anti-cancer therapies (Reed et al., 1994; Inoue-Yamauchi et al., 2017; Delbridge et al., 2016). Thus, targeting the anti-apoptotic Bcl-2 proteins represents a promising strategy for the treatment of cancer (Davids & Letai, 2012). The Bcl-2 selective inhibitor ABT-199 (Venetoclax) has excellent anti-leukemia activity against chronic lymphocytic leukemia and was approved by the FDA in April 2016 (Souers et al., 2013; Pan et al., 2014; Touzeau et al., 2014; Vaillant et al., 2013). It has proven to be an effective approach to inhibit the interaction of Bcl-2 and BH3-only
proteins by small molecules (Oltersdorf et al., 2005; Tse et al., 2008). However, the nature of dynamic protein-protein interactions and acquired resistance poses a challenge to Bcl-2 inhibitors (Zinzalla & Thurston, 2009; Choudhary et al., 2015; Juin et al., 2013). It is conceivable that targeting regulation of Bcl-2 at the transcriptional level may provide an alternative strategy for cancer therapy. Better understanding of Bcl-2 biology may have important clinical significance for better treatment of cancer.

Two promoters mediate transcriptional control of the Bcl-2 gene (Seto et al., 1988). The 5′ promoter (P1) is located 1,386 to 1,432 bp upstream of the Bcl-2 translation start site, and it is a TATA-less, GC rich promoter with multiple transcription start sites (−1,394, −1,399, −1,406, −1,410, and −1,432) and positioned in proximity to a nuclease hypersensitive site (Young & Korsmeyer, 1993). The start sites of the 3′ promoter (P2) are located 1.3 kb downstream of the P1 promoter (Onel et al., 2016). The P1 promoter is the major driver of Bcl-2 expression (Catz & Johnson, 2001; Onel et al., 2016). Several genes have been identified that regulate P1 promoter either directly or indirectly, for example, the tumor suppressor gene product p53 (Miyashita & Reed, 1995), the HIV-1 Tat protein (Zauli et al., 1995), the G-quadruplex Pu39 and P1G4 (Dai et al., 2006; Onel et al., 2016). The nuclear factor kB (Catz & Johnson, 2001) and the POU family member Brn-3a (Smith et al., 1998) have been shown to regulate the P2 promoter transcription. However, the regulation of Bcl-2 gene expression remains to be fully understood.

The PRDM10 protein belongs to the PRDM family of proteins that contain the PR domain (PRDI-BF1-RIZ1 homology domain) shared by many histone lysine methyltransferases (Huang, 2002; Mzoughi et al., 2016; Buyse, Shao & Huang, 1995; Huang, Shao & Liu, 1998). The expression pattern of PRDM10 indicates a potential role in mouse embryonic development including somite and craniofacial formation (Park & Kim, 2010; Park et al., 2013), and in corneal endothelial cell differentiation and proliferation (Rolev et al., 2017). In addition, PRDM10 protein is over-expressed in liver cancers and non-alcoholic fatty liver disease (Rolev et al., 2017; Zhang et al., 2018; Abdollahi, Zamanian & Hatami, 2017), indicating a role in facilitating tumorigenesis. Here, we studied whether PRDM10 protein may promote the action of oncogenes such as Bcl-2 gene.

MATERIAL AND METHODS

Cell culture
HEK293, MCF-7B, and Hela cell line purchased from the American Type Culture Collection-ATCC (Manassas, VA, USA). HEK293 and Hela cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS, GE Healthcare Life Sciences), 4 mM L-glutamine, 4,500 mg/l glucose at 37 °C under a atmosphere of 5% CO₂. MCF-7B cells were cultured in Roswell Park Memorial Institute (RPMI) including 10% FBS at 4 mM L-glutamine, 4,500 mg/l glucose at 37 °C under an atmosphere of 5% CO₂.

Plasmid constructs
The flag tagged full length PRDM10 expression plasmid PRDM10-pCMV4A-Flag was constructed by inserting full length PRDM10 cDNA from a human cDNA library into the
vector pCMV4A. The Bcl-2 P1 and p2 promoter-luciferase construct has been described previously (Duan, Heckman & Boxer, 2005). The Bcl-2 P1 promoter reporter plasmid was generated by inserting the (−1,386 to −1,444 bp) human Bcl-2 P1 promoter sequence in front of the firefly luciferase reporter gene as in pGL3 basic vector. The Bcl-2 p2 promoter construct was created by inserting the (−754 to +1 bp) human P2 promoter sequence (Catz & Johnson, 2001).

Transfection experiments
PRDM10-specific depletion was performed by transfecting 2 × 10^6 cells with 3ug of PRDM10-specific siRNA or Control-siRNA using Lipofectamine® 2000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instruction. Cells were harvested 48 h after the RNAi treatment. The siRNA duplexes were designed as 21-mers with 3'-dTdT overhangs and synthesized by GenePharma (Shanghai, China). PRDM10-siRNAs were directed against the PRDM10 sequence. PRDM10-siRNA-1(+) : 5’-GCUCUCAUAGACAGGUTTT- 3’ and PRDM10-siRNA-1(−) : 5’-UUAUGACUGCGAGAGTTT- 3’; PRDM10-siRNA-2(+) : 5’-CCUCAUUGCCAGUUAATT- 3’ and PRDM10-siRNA-2(−) : 5’-UUAUGACUGCGAGAGTTT- 3’; Control-siRNAs are against the sequence of luciferase: Con-siRNA(+) : 5’-UUCUCCGAACGUGUCACGUTT- 3’ Con-siRNA (−) : 5’-A CGUGACACGUGCAGAGATT- 3’. For the overexpression experiments, 2 × 10^6 cells were transfected with 3 ug of PRDM10-pCMV4A or control plasmids by using Lipofectamine® 2000. PRDM10-siRNA, control-treated and PRDM10-pCMV4A treated cells were analyzed by Western blotting.

Western blot analysis
Cell lysates were prepared by incubating for 30 min in a lysis buffer containing 25 mM Tris (pH 7.5), 75 mMNaCl, 5% glycerol, 2% SDS and protease/phosphatase inhibitors (Sigma) followed by centrifuging at 10,000 g for 10 min at room temperature. The protein concentration was measured using the BCA protein assay kit (Thermo Fisher Scientific). Proteins were separated by SDS-PAGE and transferred electrophoretically onto polyvinylidene fluoride (PVDF) membranes (Millipore), which were incubated overnight with the antibodies as described under Table S1. The bands were detected by the MiniChemi™ Chemiluminescence imaging system (Sage Creation, Beijing, China).

Total RNA isolation and quantitative RT-PCR
Total RNA was isolated using Trizol (Invitrogen) following the manufacturer’s instructions. Reverse transcription of RNA was performed using the ThermoScript RT-PCR System (Invitrogen). Quantitative PCR amplification was performed on the Bio-Rad iCycler-iQ system (Bio-Rad, Hercules, CA,USA) using the iQ-SYBR Green Supermix (Bio-Rad). Primers are described under Table S2.

Transfection and luciferase assay
HEK293 cells (8 × 10^4) were cultured in 500 µl DMEM including 10% FBS overnight using a 24 well plate at 37 °C, 5% CO₂. 1 µg of each plasmid construct was transfected into HEK293
cells using Lipofectamine® 2000 (Thermo Fisher Scientific). A Renilla luciferase plasmid, pCMV-RL (Liu et al., 2018), was co-transfected with each construct for normalization. After a further 24-hour incubation, cells were washed with phosphate buffered saline and harvested with luciferase cell culture lysis reagent from Dual-Luciferase® Reporter assay kit (Promega). Bcl-2 promoter activity in the cells was measured with the Luciferase Reporter Assay System using a Sirius luminometer (Titertek-Berthold, Bad Wildbad, Germany). Luciferase activity was calculated in relative light units and normalized to the pCMV-RL vector containing the Renilla luciferase as control reporter.

**Quantitative ChIP assay**

The ChIP assay was performed using the Agarose ChIP Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Cells were cross-linked in situ by addition of 16% formaldehyde to a final concentration of 1% and incubated at room temperature for 10 min, and then were incubated with glycine for 5 min. Cells were lysed and digested by Micrococcal Nuclease provided by the kit. The samples were then incubated with ANTI-FLAG (Sigma Aldrich, St. Louis, MO, USA), PRDM10 (abcam), IgG (Thermo Fisher Scientific), RNA Polymerase II (Thermo Fisher Scientific) antibody overnight at 4 °C on a rocking platform. ProteinA/G plus Agarose were then added to each sample and incubated for 1 h before washing them with wash buffers. Samples were then treated with elution buffer, followed by treatment with NaCl and Proteinase K. DNA was then extracted from the digested samples. Extracted DNA sample (the input sample and ChIP DNA sample) was used for quantitative PCR amplification using primers specific to promoter fragments of the Bcl-2 P1 promoter and control primers. Positive control primers were from the human β-actin gene and negative primers were from the Bcl-2 p2 promoter. Human Bcl-2 P1 promoter regions were identified using data from Ensemble (http://www.ensembl.org). They were located at human chromosome 18: 63,123,346-63,320,128. The primers for Bcl-2 P1 promoter detection were the following (product length, 107 bp): forward primer, 5′-GGCTCAGAGGAGGGCTCTTT- 3′; reverse primer, 5′-GTGCCTGTCCTCTTACTTCTTCTC- 3′ (Catz & Johnson, 2001).

**RNAseq analysis**

The mRNA expression analysis was performed using the TCGABiolinks package (v. 2.10.0) of R software (R Core Team, 2018) (Colaprico et al., 2016). Harmonized expression data (hg38) were downloaded from The Cancer Genome Atlas (TCGA) using the GDCdownload function. The RNA-Seq-based expression level was normalized by the Fragments Per Kilobase of transcript per Million mapped reads upper quartile (FPKM-UQ) method. Hexagonal heatmap of 2d bin was plotted using the geom_hex function from ggplot2 package (v. 3.1.0) (Hadley). First, counts the number of cases in each hexagon, and then maps the number of cases to the hexagon fill.

**Statistical analysis**

Differences between two groups affected by only one factor were analyzed by Mann–Whitney test. Statistical significance of differences between multiple groups was analyzed
**RESULTS**

**Human PRDM10 regulates the Bcl-2 expression**

We performed a candidate gene approach to search for cancer genes that might be regulated by PRDM10. By immunoblot approach, we found significant reduction (>2 fold) in protein levels for Bcl-2 and CCND1 but no changes for p53, MDM2, and BAX in PRDM10 depleted HEK293 cells as achieved by siRNA approach (Fig. S1). We focused on Bcl-2 for in depth analyses and further found that overexpression of PRDM10 was able to up regulate Bcl-2 protein expression (Figs. 1A and 1B). By quantitative reverse transcriptase-PCR analyses, we found that Bcl-2 mRNA levels were down-regulated by siRNA to PRDM10 and up regulated by PRDM10 overexpression (Figs. 1C and 1D).

We also tested whether PRDM10 protein contributes to Bcl-2 expression in other human cell types. We found that PRDM10 regulated Bcl-2 protein levels in Hela and MCF-7B cell by using Kruskal and Wally H test. These tests were performed using SPSS software version 19 (IBM Corporation, Armonk, NY, USA). Statistical significance was set at *P < 0.05.
Figure 2  PRDM10 effect on Bcl-2 expression in different cell lines. (A) Western blot analyses of Bcl-2 proteins upon PRDM10 depletion (siRNA-PRDM10) or PRDM10-overexpression (pCMV-4A-PRDM10) in Hela cells. (B) Bcl-2 protein levels upon PRDM10-depletion or PRDM10-overexpression in MCF-7B cells.

So, the effect of PRDM10 on Bcl-2 expression did not appear to be cell type dependent.

PRDM10 as a transcriptional activator

We next determined whether PRDM10 may regulate Bcl-2 transcription. As the P1 promoter is the major element in driving Bcl-2 transcription, we focused on this promoter in our analyses here (Petrovic et al., 1998; Young & Korsmeyer, 1993; Tsujimoto & Croce, 1986). The Bcl-2 P1 promoter reporter plasmid was generated by inserting the (−1,386 to −1,444 bp) human Bcl-2 P1 promoter sequence (Duan, Heckman & Boxer, 2007; Onel et al., 2016) in front of the firefly luciferase reporter gene as in pGL3 basic vector (Fig. 3A). The Bcl-2 p2 promoter construct was created by inserting the (−754 to +1 bp) human P2 promoter sequence (Catz & Johnson, 2001). We then carried out Dual-luciferase assays as described previously (Liu et al., 2018) on cells cotransfected with the Bcl-2 promoter construct and PRDM10 expression construct. The results showed higher luciferase activity in cells transfected with Bcl-2 P1 promoter and pCMV4A-PRDM10 (Fig. 3B). No changes were observed for the Bcl-2 p2 promoter reporter (Fig. 3B). These results suggest that PRDM10 may be a positive regulator of the Bcl-2 P1 promoter.
Figure 3  PRDM10 on Bcl-2 gene promoter activity. (A) Schematic map of human Bcl-2 gene promoter containing the 5′ (P1) promoter and 3′ (P2) promoter region. (B) Results of promoter report assay. Dual luciferase activity was measured by a luminometer at 48 h after transfection. The values represent means ± SD; n = 3; *p < 0.05, t test, two-tailed.

Full-size DOI: 10.7717/peerj.6941/fig-3

PRDM10 binding to the P1 promoters of Bcl-2 in vivo
As PRDM10 was found to regulate the P1 promoter of Bcl-2, we next determined whether PRDM10 could directly bind to the Bcl-2 P1 promoter. Based on human genomic sequences of Bcl-2 P1 gene available from the UCSC database, we designed PCR primers to cover these sites and performed chromatin immunoprecipitation (ChIP) assays and quantitative PCR to examine the binding of PRDM10 protein to the Bcl-2 P1 promoter in HEK293 cells. PRDM10 binding was detected in HEK293 cells (Figs. 4A and 4B) and also in PRDM10-Flag plasmid transfected cells (Figs. 4C and 4D).

Correlation between Bcl-2 and PRDM10 expression in cancers
As Bcl-2 is often over expressed in cancers, we next studied The Cancer Genome Atlas (TCGA) to see if Bcl-2 and PRDM10 expression may be correlated. We downloaded RNA seq datasets from the TCGA web portal for 31 cancer types and about 11,000 patient samples. PRDM10 has previously been found overexpressed in breast, ovary, kidney, colon, lung and prostate cancers (Sorrentino et al., 2018). Consistently, we found borderline positive correlation between Bcl-2 and PRDM10 expression in breast, colon, and lung cancers (Fig. 5 and Table 1). Bcl-2 is known to be highly expressed in follicular lymphomas but the TCGA dataset has no informative information for this tumor.

DISCUSSION
Here we present evidence that PRDM10 protein affected Bcl-2 gene expression at the transcriptional level. PRDM10 protein has been found overexpressed in certain cancers (Sorrentino et al., 2018) and hence may be expected to have oncogene like activities. As Bcl-2 is highly oncogenic, our study here provides a potential way for how PRDM10 may contribute to tumorigenesis. Many studies have linked the expression of Bcl-2 to the development of cancers (McDonnell et al., 1992; Lin et al., 2007; Lindner et al., 2017; Trudel et al., 1997; Yang et al., 2017). Importantly, our results showed correlation of Bcl-2 and PRDM10 expression in cancers overexpressing PRDM10. Therefore, up-regulation of Bcl-2
Figure 4  ChIP assay on Bcl-2 gene P1 promoter. (A) ChIP in endogenous HEK293 cells. PCR was performed using primers Bcl-2 P1 promoter. (B) Quantitative PCR analyses of ChIP assay of PRDM10 binding to the Bcl-2 P1 promoter in HEK293 cells. As shown, the cross-linked chromatin was precipitated with specific antibodies. The results are shown as the percentage of input DNA. (C) ChIP in transfected HEK293 cells. HEK293 cells were transfected with pCMV4A/PRDM10-Flag or pCMV-4A vectors (Negative). PCR was performed using primers Bcl-2 P1 promoter. (D) Quantitative PCR analyses of ChIP assay of PRDM10 binding to the Bcl-2 P1 promoter in transfected cells. HEK293 cells were transfected with pCMV-4A/PRDM10-Flag or pCMV-4A vectors (Negative). The values represent means ± SD; n = 3; *p < 0.05, t test, two-tailed.

by PRDM10 may be a potential mechanism for tumorigenes in cancers overexpressing PRDM10. However, the mechanisms of PRDM10 action in up-regulating gene transcription remains to be better understood.

A potential role for PRDM10 in cancer is to be highly expected since several better studied members of the PRDM family, PRDM2, PRDM3, PRDM5, and PRDM14, are known to play an important role in a variety of cancers (Huang, 2002; Entering et al., 2004; Canote et al., 2002; Deng & Huang, 2004; Nishikawa et al., 2007). While some such as PRDM2 and PRDM5 act as tumor suppressors, PRDM14 appears to be an oncogene (Nishikawa et al., 2007). The results here suggest that PRDM10 may also play an oncogenic role in cancer.

Bcl-2 protein determines the response of cancer cells to chemotherapeutic agents. In this context, the research and development of Bcl-2 inhibitors is believed to have great potential for the discovery of novel pharmacological modulators in cancer. It was reported that ABT-199 has promising activity against preclinical models in some cancers (Sasi et al., 2019; Flinn et al., 2019; Lok et al., 2019). Results of a phase II clinical trial have shown...
Figure 5  Pooled analyses on the Correlation between Bcl-2 and PRDM10 expression in cancers. Hexagonal heatmap of correlation between expression of Bcl-2 and PRDM10 in the primary solid tumor tissues of breast invasive carcinoma (BRCA, left), colon adenocarcinoma (COAD, middle), and lung squamous cell carcinoma (LUSC, right). The x-axis and y-axis represent the value of log2 FPKM. The $r$ represents the value of Pearson’s correlation coefficient, $p$ represents the $p$-value of test for the Pearson’s correlation coefficient.

Table 1  Number of samples.

| Abbr. | Cancers                          | N of samples |
|-------|----------------------------------|--------------|
| BRCA  | Breast Invasive Carcinoma        | 1,102        |
| COAD  | Colon Adenocarcinoma             | 478          |
| LUSC  | Lung Squamous Cell Carcinoma     | 502          |

that ABT-199 has promising clinical activity compared to current alternatives, but relapse remains a concern (Rogers et al., 2018; De Vos et al., 2018). Combinations such as ABT-199 with decitabine or azacitidine can help induce remission but lack improvement in overall survival (DiNardo et al., 2019; Rahmat et al., 2018). Thus, new combinations involving ABT-199 are urgently needed to manage cancer remission. Elucidating the regulation of the Bcl-2 expression may provide new opportunities for designing anti-Bcl-2 agents.

CONCLUSIONS

We here found that PRDM10 could bind to the p1 promoter of Bcl-2 and contribute to its expression. Like its related PR domain genes, PRDM10 also displays properties of transcription factors with a potential role in tumorigenesis. Future studies will be required to determine whether siRNA targeting PRDM10 may serve as novel cancer therapy agents by inhibiting Bcl-2 expression.
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This study was supported by the National Natural Science Foundation of China (81171880, 81330027, 81525007 and 31400919), the National Basic Research Program of China (2011CB51001, 2012CB517900), and the excellent youth science research program of the Education Department of Hunan Province (14B183). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
National Natural Science Foundation of China: 81171880, 81330027, 81525007, 31400919.
National Basic Research Program of China: 2011CB51001, 2012CB517900.
Education Department of Hunan Province: 14B183.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Na Chen conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
• Taobo Hu and Zhihong Li analyzed the data, prepared figures and/or tables.
• Yuanyuan Gui contributed reagents/materials/analysis tools.
• Jieying Gao performed the experiments, contributed reagents/materials/analysis tools.
• Shi Huang conceived and designed the experiments, authored or reviewed drafts of the paper, approved the final draft.

Data Availability
The following information was supplied regarding data availability:
The raw measurements are available in the Supplemental File.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.6941#supplemental-information.

REFERENCES
Abdollahi H, Zamanian AM, Hatami B. 2017. Protein interaction mapping interpretation of none alcoholic fatty liver disease model of rats after fat diet feeding. Gastroenterology and Hepatology from Bed to Bench 10(Suppl1):S146–S153.
Aird D, Teng T, Huang CL, Pazolli E, Banka D, Cheung-Ong K, Eifert C, Furman C, Wu ZJ, Seiler M, Buonomici S, Fekkes P, Karr C, Palacino J, Park E, Smith PG, Yu L, Mizui Y, Warmuth M, Chicas A, Corson L, Zhu P. 2019. Sensitivity to splicing
modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators. *Nature Communications* **10**:137 DOI 10.1038/s41467-018-08150-5.

**Buyse IM, Shao G, Huang S. 1995.** The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. *Proceedings of the National Academy of Sciences of the United States of America* **92**(10):4467–4471 DOI 10.1073/pnas.92.10.4467.

**Canote R, Du Y, Carling T, Tian F, Peng Z, Huang S. 2002.** The tumor suppressor gene RIZ in cancer gene therapy (review). *Oncology Reports* **9**(1):57–60.

**Catz SD, Johnson JL. 2001.** Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. *Oncogene* **20**:7342–7351 DOI 10.1038/sj.onc.1204926.

**Chao DT, Korsmeyer SJ. 1998.** BCL-2 family: regulators of cell death. *Annual Review of Immunology* **16**:395–419 DOI 10.1146/annurev.immunol.16.1.395.

**Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A. 2015.** MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. *Cell Death & Disease* **6**:e1593 DOI 10.1038/cddis.2014.525.

**Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, Ceccarelli M, Bontempi G, Noushmehr H. 2016.** TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Research* **44**(8):e71 DOI 10.1093/nar/gkv1507.

**Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A. 2015.** MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. *Cell Death & Disease* **6**:e1593 DOI 10.1038/cddis.2014.525.

**Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, Ceccarelli M, Bontempi G, Noushmehr H. 2016.** TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Research* **44**(8):e71 DOI 10.1093/nar/gkv1507.

**Dai J, Dexheimer TS, Chen D, Carver M, Ambrus A, Jones RA, Yang D. 2006.** An intramolecular G-quadruplex structure with mixed parallel/antiparallel G-strands formed in the human BCL-2 promoter region in solution. *Journal of the American Chemical Society* **128**(4):1096–1098 DOI 10.1021/ja055636a.

**Davids MS, Letai A. 2012.** Targeting the B-cell lymphoma/leukemia 2 family in cancer. *Journal of Clinical Oncology* **30**:3127–3135 DOI 10.1200/JCO.2011.37.0981.

**De Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, Vlummens P, Fostier K, Kassambara A, Moreaux J, Van Ginderachter JA, De Bruyne E, Van derkenken K, Van Valckenborgh E. 2018.** Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. *Cancer Letters* Epub ahead of print 2019 Feb 1 DOI 10.1016/j.canlet.2018.11.002.

**De Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR. 2018.** Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. *Annals of Oncology* **29**:1932–1938 DOI 10.1093/annonc/mdy256.

**Delbridge AR, Grabow S, Strasser A, Vaux DL. 2016.** Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. *Nature Reviews Cancer* **16**:99–109 DOI 10.1038/nrc.2015.17.

**Deng Q, Huang S. 2004.** PRDM5 is silenced in human cancers and has growth suppressive activities. *Oncogene* **23**:4903–4910 DOI 10.1038/sj.onc.1207615.

**DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J,
Pollyea DA, Letai A. 2019. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7–17 DOI 10.1182/blood-2018-08-868752.

Duan H, Heckman CA, Boxer LM. 2005. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Molecular and Cellular Biology 25:1608–1619 DOI 10.1128/MCB.25.5.1608-1619.2005.

Duan H, Heckman CA, Boxer LM. 2007. The immunoglobulin heavy-chain gene 3′ enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells. Oncogene 26:2635–2641 DOI 10.1038/sj.onc.1210061.

Emterling A, Wallin A, Arbman G, Sun XF. 2004. Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer. Annals of Oncology 15:242–246 DOI 10.1093/annonc/mdh045.

Flinn IW, Gribben JG, Dyer M, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Padmanabhan IS, Quillet-Mary A, Ysebaert L, Walter HS, Verduzo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. 2019. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood Epub ahead of print 2019 Mar 12 DOI 10.1182/blood-2019-01-896290.

Hadley W. 2009. ggplot2. In: Elegant graphics for data analysis. New York: Springer.

Huang S. 2002. Histone methyltransferases, diet nutrients and tumour suppressors. Nature Reviews Cancer 2:469–476 DOI 10.1038/nrc819.

Huang S, Shao G, Liu L. 1998. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. Journal of Biological Chemistry 273:15933–15939 DOI 10.1074/jbc.273.26.15933.

Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, Hellmann MD, Kris MG, Hsieh JJ, Cheng EH. 2017. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nature Communications 8:16078 DOI 10.1038/ncomms16078.

Juin P, Geneste O, Gautier F, Depil S, Campone M. 2013. Decoding and unlocking the BCL-2 dependency of cancer cells. Nature Reviews Cancer 13:455–465 DOI 10.1038/nrc3538.

Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2(3):183–192 DOI 10.1016/S1535-6108(02)00127-7.

Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM, Xiang J. 2007. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Research 17:531–536 DOI 10.1038/cr.2007.12.
Lindner AU, Salvucci M, Morgan C, Monsefi N, Resler AJ, Cremona M, Curry S, Toomey S, O’Byrne R, Bacon O, Stuhler M, Flanagan L, Wilson R, Johnston PG, Salto-Tellez M, Camilleri-Broet S, McNamara DA, Kay EW, Hennessy BT, Laurent-Puig P, Van Schaeybroeck S, Prehn J. 2017. BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut 66:2141–2148 DOI 10.1136/gutjnl-2016-312287.

Liu Q, Qu X, Xie X, He P, Huang S. 2018. Repression of Akt3 gene transcription by the tumor suppressor RIZ1. Scientific Reports 8:1528 DOI 10.1038/s41598-018-19943-5.

Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin A, Desai J, Ptouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Bujak AZ, Dawson SJ, Gray D, Visvader JE, Lindeman GJ. 2019. A Phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer. Cancer Discovery 9:354–369 DOI 10.1158/2159-8290.CD-18-1151.

Martin LA, Dowsett M. 2013. BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer? Cancer Cell 24(1):7–9 DOI 10.1016/j.ccr.2013.06.006.

McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung IW, Hsieh JT, Tu SM, Campbell ML. 1992. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Research 52:6940–6944.

Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299 DOI 10.1016/0092-8674(95)90412-3.

Mzoughi S, Tan YX, Low D, Guccione E. 2016. The role of PRDMs in cancer: one family, two sides. Current Opinion in Genetics & Development 36:83–91 DOI 10.1016/j.gde.2016.03.009.

Nishikawa N, Toyota M, Suzuki H, Honma T, Fujikane T, Ohmura T, Nishidate T, Ohe-Toyota M, Maruyama R, Sonoda T, Sasaki Y, Urano T, Imai K, Hirata K, Tokino T. 2007. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Research 67:9649–9657 DOI 10.1158/0008-5472.CAN-06-4111.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Boll BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li G, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O’Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomasselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681 DOI 10.1038/nature03579.

Onel B, Carver M, Wu G, Timonina D, Kalarn S, Larriva M, Yang D. 2016. A new G-quadruplex with hairpin loop immediately upstream of the human BCL2 P1 promoter modulates transcription. Journal of the American Chemical Society 138:2563–2570 DOI 10.1021/jacs.5b08596.

Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Dohner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach
T, Harutyunyan KG, Hu J, Leversion JD, Marcucci G, Muschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. 2014. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discovery 4:362–375 DOI 10.1158/2159-8290.CD-13-0609.

Park JA, Kim KC. 2010. Expression patterns of PRDM10 during mouse embryonic development. BMB Reports 43(1):29–33 DOI 10.5483/BMBRep.2010.43.1.029.

Park J, Kim T, Lee B, Kwon E, Kim K. 2013. Expression of PRDM10 in arthritic synovial derived tissues. Genes & Genomics 35:685–691 DOI 10.1007/s13258-013-0119-z.

Petrovic AS, Young RL, Hilgarth B, Ambros P, Korsmeyer SJ, Jaeger U. 1998. The Ig heavy chain 3′ end confers a posttranscriptional processing advantage to Bcl-2-IgH fusion RNA in t(14;18) lymphoma. Blood 91(10):3952–3961.

R Core Team. 2018. R: a language and environment for statistical computing. Version 3.5.1. Vienna: R Foundation for Statistical Computing. Available at https://www.R-project.org/.

Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN. 2018. Venetoclax in combination with decitabine for relapsed T-Cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant. Case Reports in Hematology 2018:6092646 DOI 10.1155/2018/6092646.

Reed JC, Kitada S, Takayama S, Miyashita T. 1994. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin’s lymphoma and lymphocytic leukemia cell lines. Annals of Oncology 5(Suppl 1):61–65 DOI 10.1093/annonc/5.suppl_1.S61.

Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, Lozanski G, Maddocks KJ, Moran ME, Reid MA, Lucas M, Woyach JA, Whitlow WT, Jones JA, Byrd JC. 2018. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132(15):1568–1572 DOI 10.1182/blood-2018-05-853564.

Rolev K, O’Donovan DG, Georgiou C, Rajan MS, Chittka A. 2017. Identification of Prdm genes in human corneal endothelium. Experimental Eye Research 159:114–122 DOI 10.1016/j.exer.2017.02.009.

Sasi BK, Martines C, Xerxa E, Porro F, Kalkan H, Fazio R, Turkalj S, Bojnik E, Pyrzyńska B, Stachura J, Zerrouqi A, Bobrowicz M, Winiarska M, Priebe V, Bertoni F, Mansouri L, Rosenquist R, Efremov DG. 2019. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. Leukemia Epub ahead of print 2019 Mar 14 DOI 10.1038/s41375-019-0442-8.

Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, Korsmeyer SJ. 1988. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO Journal 7:123–131 DOI 10.1002/j.1460-2075.1988.tb02791.x.

Smith MD, Ensor EA, Coffin RS, Boxer LM, Latchman DS. 1998. Bcl-2 transcription from the proximal P2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor. Journal of Biological Chemistry 273:16715–16722 DOI 10.1074/jbc.273.27.16715.
Sorrentino A, Federico A, Rienzo M, Gazzerro P, Bifulco M, Ciccodicola A, Casamas-simi A, Abbondanza C. 2018. PR/SET domain family and cancer: novel insights from The Cancer Genome Atlas. International Journal of Molecular Sciences 19(10):E3250 DOI 10.3390/ijms19103250.

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerrickhouse RA, Rosenberg SH, Elmore SW. 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine 19:202–208 DOI 10.1038/nm.3048.

Touzeau C, Dousset C, Le Gouill S, Sampath D, Leversen JD, Souers AJ, Maiga S, Bene MC, Moreau P, Pellat-Deceunynck C, Amiot M. 2014. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 28(1):210–212 DOI 10.1038/leu.2013.216.

Trudel M, Lanoix J, Barisoni L, Blouin MJ, Desforges M, L’Italien C, D’Agati V. 1997. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. Journal of Experimental Medicine 186:1873–1884 DOI 10.1084/jem.186.11.1873.

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. 2008. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research 68:3421–3428 DOI 10.1158/0008-5472.CAN-07-5836.

Tsujimoto Y, Croce CM. 1986. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proceedings of the National Academy of Sciences of the United States of America 83:5214–5218 DOI 10.1073/pnas.83.14.5214.

Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GI. 2013. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24(1):120–129 DOI 10.1016/j.ccr.2013.06.002.

Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. 2001. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20:240–251 DOI 10.1038/sj.onc.1204067.

Yang H, Lee MH, Park I, Jeon H, Choi J, Seo S, Kim SW, Koh GY, Park KS, Lee DH. 2017. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. Cancer Letters 411:19–26 DOI 10.1016/j.canlet.2017.09.040.

Young RL, Korsmeyer SJ. 1993. A negative regulatory element in the bcl-2 5′- untranslated region inhibits expression from an upstream promoter. Molecular and Cellular Biology 13:3686–3697 DOI 10.1128/MCB.13.6.3686.

Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, Mazzoni M, Capitani S. 1995. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2
gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. *Blood* 86(10):3823–3834.

**Zhang L, Huang Y, Ling J, Zhuo W, Yu Z, Shao M, Luo Y, Zhu Y. 2018.** Screening and function analysis of hub genes and pathways in hepatocellular carcinoma via bioinformatics approaches. *Cancer Biomarkers* 22(3):511–521 DOI 10.3233/CBM-171160.

**Zinzalla G, Thurston DE. 2009.** Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. *Future Medicinal Chemistry* 1(1):65–93 DOI 10.4155/fmc.09.12.